Pacer Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Pacer Advisors’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-376,840	Closed	-$9.09M	–	3832
2025 Q3	$9.09M	Buy	+376,840	New	+$7.89M	0.02%	506

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pacer Advisors's INDV Position: Q4 2025 in Review

Pacer Advisors sold out of Indivior Pharmaceuticals (INDV) in Q4 2025, closing a stake of 376,840 shares — an estimated $9.09M sold.

Pacer Advisors first reported a position in INDV in Q3 2025 and held it in 1 quarter. The position peaked at $9.09M in Q3 2025. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

Pacer Advisors reported no remaining Indivior Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Pacer Advisors sold 376,840 Indivior Pharmaceuticals shares in Q4 2025, an estimated $9.09M.
Pacer Advisors first reported a position in Indivior Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Pacer Advisors's Indivior Pharmaceuticals position peaked at $9.09M in Q3 2025.
259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on Pacer Advisors's 13F filing for Q4 2025, filed 4 Feb 2026.